{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-061933","form_type":"8-K","ticker":"RZLT","cik":"0001509261","company_name":"Rezolute, Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.741653+00:00","generated_at":"2026-06-01T22:59:11.485293+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Rezolute reports Q3 FY2024 net loss $17.1M; sunRIZE Phase 3 enrolling, DME Phase 2 topline expected May 2024","bullets":["Net loss $17.1M for Q3 FY2024 vs $15.7M YoY; cash and equivalents $81.6M (down from $118.4M in June 2023).","sunRIZE Phase 3 for cHI (RZ358) enrolling; completion expected end-2024; topline data mid-2025.","Completed in-vivo tox study in brown Norway rats at 40 mg/kg; no liver abnormalities; to submit to FDA summer 2024.","DME Phase 2 (RZ402) completed dosing of 94 patients; topline results expected May 2024.","FDA alignment for potential registrational study in tumor HI; 5 insulinoma patients treated under Expanded Access."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-061933","json":"https://secwatch.observer/filing/0001104659-24-061933.json","markdown":"https://secwatch.observer/filing/0001104659-24-061933.md","text":"https://secwatch.observer/filing/0001104659-24-061933.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1509261/000110465924061933/0001104659-24-061933-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1509261/000110465924061933/tm2414592d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T22:59:11.485293+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b260ae9750ddd938a69694665e03c340d06c37a9","claim":"Rezolute, Inc. reported the three months ended March 31, 2024 results: net income $17.1 million.","evidence_excerpt":"Net loss was $17.1 million for the third quarter of fiscal 2024 compared with a net loss of $15.7 million for the same period a year ago.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1509261/000110465924061933/0001104659-24-061933-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2024"},{"label":"Net income","value":"$17.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}